LOL - I only saw your comment after I posted saying I wouldn't be taking the trouble. :) Your request has been met. :)
It's not too much trouble but seems rather pointless. I'll respectfully decline to continue on that particular point any further. It seems a bit pointless to continue to debate on what Ev meant or didn't mean...and who is right about it. Opinions aren't right or wrong, they're simply opinions We see it differently. I'm good with that.
As for comments meeting approval and all that....I find this beginning to get personal and argumentative for no good reason. As you say, we're here to toss our thoughts and learn. Taking it personally when someone has a different point of view than you is counter-productive in my opinion. Not interested in pursuing this line of discussion with you.
Appears somewhat that the favor Alinia had 2 or 3 years ago is being eclipsed by PIs, DAAs and other up and comers. The new technologies of targeted therapies has the spotlight and certainly has the potential to steal the show if approved, but if the FDA drags its feet on approval it's possible more hepas will start looking back on Alinia with more interest.
May I request that you not take the trouble?
If it's not too much trouble could you please explain what your interpretation of Evangelin's statement " but it probably would increase his chances of Teleprevir getting him an SVR" because I took "it" to mean Alinia so I find it unreasonable of you to accuse me of jumping in and changing the direction of the discussion. You know what my reply to that was because you quoted me. Evangelin later clarified her comment on another post so my other question to you is.... ideally, in what direction do you think the conversation should have gone?
After all, despite how you see it, this is a discussion group and we're all here to learn and toss out our thoughts. As far as I know my comments do not have to meet your approval or that of anyone else.
__________________________________________________________________________
Lovebird, you are exactly right. Developing a resistance to a DAA should be a big big concern, especially for those with cirrhosis.
The flip side of this discussion would be interesting fodder, too:
considering PIs are increasing the SVR rates for relapsers and null-responders but not as significantly as naives... and there are considerable higher risks with PI use than with Alinia use (which has been approximated to improve SVR by 10% in previous g1 non-responders...)
Perhaps they'll be takers of Alinia+SOC as a 1st attempt, especially if they're CC or CT, and PIs as a 2nd try? Just saying...